Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
1 study found for:    15156165 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed High-Dose Melphalan Plus Peripheral Stem Cell Transplantation in Treating Patients With Primary Systemic Amyloidosis
Condition: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: Biological: filgrastim;   Drug: melphalan;   Procedure: bone marrow ablation with stem cell support;   Procedure: peripheral blood stem cell transplantation

Indicates status has not been verified in more than two years